Bleeding Disorders affects a significant proportion of the population worldwide. Hemophilia A and B and Von Willebrand’s disease are common bleeding disorders that occurs due to Coagulation factor Deficiencies.
The limited diagnosis and treatment option for Bleeding Disorders affect the quality of life of the patients and also life expectancy. However, to fulfil the unmet need in the Bleeding Disorders treatment market, companies such as BioMarin Pharmaceutical, Biotest AG, Bristol Myers Squibb, Catalyst Biosciences, CSL Behring, GC Pharma, Grifols, Kezar Life Sciences, LFB, Novo Nordisk, Octapharma, Pfizer, Principia Biopharma, Protalex, Sangamo Therapeutics, Sanofi, Spark Therapeutics, UCB Biopharma SPRL, uniQure, and others are diligently working toward the development of novel therapeutic options. Similarly, in the coming years the launch of emerging therapies, rising awareness, increasing healthcare spending, and regulatory approval will stimulate the Bleeding Disorders market growth.
For more details, visit: Bleeding Disorders Market Growth